Table 5.

CGRP increased CRE-dependent gene activity in neuron-enriched spinal cord cultures

Treatment	cAMP (pmol/mg of protein)	Luciferase activity (% of basal)
Basal	16  ± 1 (15)	98  ± 9 (15)
CGRP (2 × 300 nm)	367  ± 22 (17)5-150	330  ± 29 (17)5-150
CGRP8–37 (3 μm)	20  ± 10 (17)	140  ± 17 (14)
CGRP + CGRP8–37	118  ± 10 (17)5-160	212  ± 19 (17)

Multiple treatments occurred at 2 hr intervals. Samples for cAMP were collected 10 min after the last addition of the drug. For determination of CRE-dependent gene expression, treatments were initiated 24 hr after transfection with CRE-luciferase DNA, and samples were collected for assay approximately 21 hr after initiation of treatment. Luciferase activity was normalized to basal levels within the same culture preparation. Numbers in parentheses are numbers of wells per treatment (five or six wells per treatment per experiment; three experiments per treatment). Values were deleted from the data set for luciferase activity if they were <2 SDs below the mean for basal luciferase activity or >2 SDs above the mean for a treatment group. No more than four values were deleted from any treatment group, and the deleted values were evenly distributed between these two conditions.

F5-150: p < 0.001 compared with all other groups within the measure.

F5-160: p < 0.05 compared with antagonist alone (one-way ANOVA with Tukey's multiple-comparisons test).